Cumulative incidence of primary and secondary outcomes by thrombocytopenia status
| Outcome (within 1 y of SpVT diagnosis) . | Overall cohort N = 581 . | Platelet <100 × 103/μL n = 202 . | Platelet ≥100 × 103/μL n = 310 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n . | Incidence (95% CI) . | Time to event (d), median (IQR) . | n . | Incidence (95% CI) . | Time to event (d), median (IQR) . | n . | Incidence (95% CI) . | Time to event (d), median (IQR) . | |
| Major bleeding | 62 | 10.7% (8.2-13.2) | 70.0 (17.0-146) | 21 | 10.4% (6.2-14.6) | 23.0 (12.0-146) | 34 | 11.0% (7.5-14.5) | 77.0 (23.0-144) |
| Upper GI | 43 | 7.4% (5.3-9.5) | 75.0 (14.0-160) | 13 | 6.4% (3.1-9.8) | 13.0 (3.0-146) | 24 | 7.7% (4.8-10.7) | 82.0 (22.5-152) |
| Lower GI | 4 | 0.7% (0.02-1.4) | 55.5 (37.0-83.0) | 1 | 0.5% (0.00-1.5) | 46.0 (46.0-46.0) | 3 | 1.0% (0.00-2.1) | 65.0 (28.0-101) |
| Intracranial | 5 | 0.9% (0.01-1.6) | 129 (110-244) | 2 | 1.0% (0.00-2.4) | 187 (129-244) | 2 | 0.7% (0.00-1.5) | 141 (21.0-261) |
| Retroperitoneal | 2 | 0.3% (0.00-0.08) | 23.5 (6.0-41.0) | 0 | 0.0% | -- | 2 | 0.7% (0.00-1.5) | 23.5 (6.0-41.0) |
| Intraarticular/intramuscular | 3 | 0.5% (0.00-1.1) | 23.0 (16.0-54.0) | 3 | 1.5% (0.00-3.2) | 23.0 (16.0-54.0) | 0 | 0.0% | -- |
| Mucocutaneous | 0 | 0.0% | -- | 0 | 0.0% | -- | 0 | 0.0% | -- |
| Pericardial | 0 | 0.0% | -- | 0 | 0.0% | -- | 0 | 0.0% | -- |
| CRNMB | 36 | 6.2% (4.2-8.2) | 56.0 (19.0-117) | 13 | 6.4% (3.1-9.8) | 97.0 (55.0-220) | 18 | 5.8% (3.2-8.4) | 21.5 (5.0-90.0) |
| Clinically relevant bleeding | 98 | 16.9% (13.8-19.9) | 60.5 (18.0-141) | 34 | 16.8% (11.7-22.0) | 55.5 (16.0-154) | 52 | 16.8% (12.6-20.9) | 56.0 (20.5-101) |
| Progression and/or recurrence of SpVT∗ | 94 | 16.2% (13.2-19.2) | 87.0 (51.0-146) | 29 | 14.4% (9.5-19.2) | 82.0 (37.0-161) | 40 | 12.9% (9.2-16.6) | 73.0 (44.5-125) |
| Progression | 79 | 13.6% (10.8-16.4) | 89.0 (56.0-151) | 24 | 11.9% (7.4-16.3) | 81.0 (37.5-159) | 33 | 10.7% (7.2-14.1) | 87.0 (56.0-130) |
| Recurrence | 20 | 3.4% (2.0-4.9) | 110 (24.5-195) | 6 | 3.0% (0.6-5.3) | 174 (17.0-224) | 8 | 2.6% (0.8-4.4) | 53.0 (15.5-95.5) |
| Usual-site VTE (DVT or PE) | 30 | 5.2% (3.4-7.0) | 80.5 (43.0-137) | 5 | 2.5% (0.3-4.6) | 134 (92.0-174) | 21 | 6.8% (4.0-9.6) | 71.0 (43.0-137) |
| DVT | 16 | 2.8% (1.4-4.1) | 81.0 (35.5-185) | 5 | 2.5% (0.3-4.6) | 134 (92.0-174) | 9 | 2.9% (1.0-4.8) | 66.0 (43.0-196) |
| PE | 14 | 2.4% (1.2-4.0) | 80.5 (54.0-100) | 0 | 0.0% | -- | 12 | 3.9% (1.7-6.0) | 77.0 (48.0-119) |
| Outcome (within 1 y of SpVT diagnosis) . | Overall cohort N = 581 . | Platelet <100 × 103/μL n = 202 . | Platelet ≥100 × 103/μL n = 310 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n . | Incidence (95% CI) . | Time to event (d), median (IQR) . | n . | Incidence (95% CI) . | Time to event (d), median (IQR) . | n . | Incidence (95% CI) . | Time to event (d), median (IQR) . | |
| Major bleeding | 62 | 10.7% (8.2-13.2) | 70.0 (17.0-146) | 21 | 10.4% (6.2-14.6) | 23.0 (12.0-146) | 34 | 11.0% (7.5-14.5) | 77.0 (23.0-144) |
| Upper GI | 43 | 7.4% (5.3-9.5) | 75.0 (14.0-160) | 13 | 6.4% (3.1-9.8) | 13.0 (3.0-146) | 24 | 7.7% (4.8-10.7) | 82.0 (22.5-152) |
| Lower GI | 4 | 0.7% (0.02-1.4) | 55.5 (37.0-83.0) | 1 | 0.5% (0.00-1.5) | 46.0 (46.0-46.0) | 3 | 1.0% (0.00-2.1) | 65.0 (28.0-101) |
| Intracranial | 5 | 0.9% (0.01-1.6) | 129 (110-244) | 2 | 1.0% (0.00-2.4) | 187 (129-244) | 2 | 0.7% (0.00-1.5) | 141 (21.0-261) |
| Retroperitoneal | 2 | 0.3% (0.00-0.08) | 23.5 (6.0-41.0) | 0 | 0.0% | -- | 2 | 0.7% (0.00-1.5) | 23.5 (6.0-41.0) |
| Intraarticular/intramuscular | 3 | 0.5% (0.00-1.1) | 23.0 (16.0-54.0) | 3 | 1.5% (0.00-3.2) | 23.0 (16.0-54.0) | 0 | 0.0% | -- |
| Mucocutaneous | 0 | 0.0% | -- | 0 | 0.0% | -- | 0 | 0.0% | -- |
| Pericardial | 0 | 0.0% | -- | 0 | 0.0% | -- | 0 | 0.0% | -- |
| CRNMB | 36 | 6.2% (4.2-8.2) | 56.0 (19.0-117) | 13 | 6.4% (3.1-9.8) | 97.0 (55.0-220) | 18 | 5.8% (3.2-8.4) | 21.5 (5.0-90.0) |
| Clinically relevant bleeding | 98 | 16.9% (13.8-19.9) | 60.5 (18.0-141) | 34 | 16.8% (11.7-22.0) | 55.5 (16.0-154) | 52 | 16.8% (12.6-20.9) | 56.0 (20.5-101) |
| Progression and/or recurrence of SpVT∗ | 94 | 16.2% (13.2-19.2) | 87.0 (51.0-146) | 29 | 14.4% (9.5-19.2) | 82.0 (37.0-161) | 40 | 12.9% (9.2-16.6) | 73.0 (44.5-125) |
| Progression | 79 | 13.6% (10.8-16.4) | 89.0 (56.0-151) | 24 | 11.9% (7.4-16.3) | 81.0 (37.5-159) | 33 | 10.7% (7.2-14.1) | 87.0 (56.0-130) |
| Recurrence | 20 | 3.4% (2.0-4.9) | 110 (24.5-195) | 6 | 3.0% (0.6-5.3) | 174 (17.0-224) | 8 | 2.6% (0.8-4.4) | 53.0 (15.5-95.5) |
| Usual-site VTE (DVT or PE) | 30 | 5.2% (3.4-7.0) | 80.5 (43.0-137) | 5 | 2.5% (0.3-4.6) | 134 (92.0-174) | 21 | 6.8% (4.0-9.6) | 71.0 (43.0-137) |
| DVT | 16 | 2.8% (1.4-4.1) | 81.0 (35.5-185) | 5 | 2.5% (0.3-4.6) | 134 (92.0-174) | 9 | 2.9% (1.0-4.8) | 66.0 (43.0-196) |
| PE | 14 | 2.4% (1.2-4.0) | 80.5 (54.0-100) | 0 | 0.0% | -- | 12 | 3.9% (1.7-6.0) | 77.0 (48.0-119) |
DVT, deep vein thrombosis; IQR, interquartile range; PE, pulmonary embolism.
For patients with progression and recurrence, time to event is time to the earlier event.